🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHas anyone dealt with a1c target achievement rates? Page 2

Has anyone dealt with a1c target achievement rates?

Dr.NephBHM_UK Fri, Apr 25, 2025 at 7:51 AM 9 replies 1,380 viewsPage 2 of 2
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Apr 25, 2025 at 10:41 AM#6

Does anyone know if insurance continues to cover semaglutide once the diabetes diagnosis is removed? That's my concern — I'm in a similar trajectory and worried about losing coverage.

Last edited: Apr 25, 2025 at 4:41 PM
44 13Admin, Dr.Martinez, mike_mod and 41 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Apr 25, 2025 at 10:58 AM#7
Does anyone know if insurance continues to cover semaglutide once the diabetes diagnosis is removed?

This varies hugely by plan. Some will switch the indication to obesity management (BMI-based), some require a new prior auth, and some will drop coverage entirely. It's worth having a proactive conversation with your endo about coding strategy before the diagnosis is officially changed. Some docs will keep "insulin resistance" or "pre-diabetes" as a code even after A1C normalizes, which can preserve coverage.

17 24KarenAZ_mom, zoe_NC, Dr.ObesityLA and 14 others
Reply Quote Save Share Report
RickReta_CO
Member
312
1,234
Jan 2025
Colorado
Apr 25, 2025 at 11:15 AM#8

Good point about insurance. My endo is keeping me coded as "obesity, BMI 31.5" which is still accurate and is a covered indication on my plan. She was very thoughtful about the timing. The T2D history code is also documented which helps with prior auths.

9 24hyun_seoul, jim_asheville, matt_MKE and 6 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Apr 25, 2025 at 11:32 AM#9

For those who like numbers, here's what the research says about this kind of trajectory:

The STEP 2 trial showed an average A1C reduction of 1.6 percentage points on semaglutide 2.4mg in patients with T2D. An A1C drop of 3.8 points (9.2 to 5.4) is well above average, which suggests diet/exercise modifications played a significant complementary role. The weight loss of 66 lbs (~25%) is also above the trial average of ~10%, further supporting that lifestyle changes amplified the pharmacological effect.

Great result. The data backs up the approach.

Last edited: Apr 25, 2025 at 12:32 PM
21 6VendorMark, COA_Karl, MikeFit_NJ and 18 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register